Bajaj Healthcare Secures DCGI Approval for Cenobamate

Bajaj Healthcare has received approval from the Drugs Controller General of India (DCGI) to manufacture and market Cenobamate.

Reader Takeaway: First-mover advantage in a high-value CNS drug; commercial launch execution is key.

What just happened

Bajaj Healthcare announced it has received regulatory clearance from the DCGI to produce and sell Cenobamate, an antiseizure medication. The approval covers the Active Pharmaceutical Ingredient (API) and tablet forms in six strengths: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

Why this matters

This approval makes Bajaj Healthcare the first company to launch Cenobamate in India. Management views Cenobamate as a complex, high-value product and its introduction is a strategic move to deepen the company's presence in the Central Nervous System (CNS) therapeutic segment. This first-mover advantage could provide a competitive edge and expand its specialized therapies portfolio.

The backstory

The DCGI approval follows a recommendation from the Subject Expert Committee in June 2026. This marks a successful progression through the regulatory pathway for a specialized pharmaceutical product.

What changes now

The company can now proceed with the commercial manufacturing and marketing of Cenobamate in India. This is expected to bolster its CNS franchise and contribute to its portfolio of differentiated, high-complexity pharmaceutical offerings.

Risks to watch

While the regulatory approval is a significant milestone, investors will need to monitor the successful commercial rollout of Cenobamate and its ability to scale effectively in the Indian market. The profitability and market acceptance will be crucial.

Peer comparison

Information on specific peers launching Cenobamate in India is not immediately available, but the company's move positions it uniquely in this niche therapeutic area.

Context metrics (time-bound)

• Regulatory Approval Received: DCGI approval granted.
• Previous Recommendation: Subject Expert Committee recommendation in June 2026.

What to track next

Investors should closely watch the commercial launch progress, market uptake, and the product's contribution to Bajaj Healthcare's revenue and profitability in the coming quarters.